The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ICML 2021 | Strategies to achieve deep remission pre-transplant
Barbara Eichhorst, MD, University Hospital Cologne, Cologne, Germany, explains how deep remission can be achieved in chronic lymphocytic leukemia (CLL) patients who have yet to undergo transplantation. Despite a combination of allogeneic stem cell transplantation and targeted therapies being an option for achieving remission, stem cell transplantation is not carried out in patients who are in first remission. Introduction of alternative cell therapies such as bispecific antibodies can benefit patients who are resistant to existing targeted therapies and are yet to receive stem cell transplantation. This is interview took place during the 2021 International Conference on Malignant Lymphoma (16-ICML).
